- Before
- Owns 29 open items across 4 products and 8 agencies, and worries less about the requirements in the letters than about what the company said in a meeting months ago.
- Now
- Sees the dates owed on one timeline, each linked to its page; the promise in the minutes is found and added with one signature.
Three FDA letters, and the promise in the minutes nobody tracked
A drug maker has four marketed products, one of them inherited in an acquisition, and 29 open items with 8 health authorities. One morning, three new FDA letters are waiting. Here is what happens next, screen by screen, in the working solution.
A worked example on sample data. Names, IDs and figures on the screens and in this section come from the demo.
- 01Morning
All dates owed to agencies, on one timeline
Regulatory leadThe lead's home screen is a timeline by product: requirements as circles, commitments and promises as squares, colored at risk, watch, on track or later. The red one is on the company's biologic: a post-marketing commitment to re-evaluate the HMW species limits, due in 24 days, with only 21 of the 30 commercial lots made. The panel shows where the date comes from: the approval letter for the BLA, page 2, in FDA's own words.
“Every date links to the page it came from.”
- 02One click
“Read 3 new letters”: five steps, in view
The agentsThe Correspondence Reader classifies a supplement approval for the biologic, a fulfillment letter for a postmarketing requirement on a second product, and Type B minutes for that second product. The Commitment Extractor finds 6 items with their page and exact words and sets a standing reminder aside. The Change & Duplicate Checker sorts them: 4 new, 1 change to an existing commitment, 1 requirement fulfilled.
“Proposed dates are on the timeline, dashed. Nothing is final until you sign.”
- 03Seconds later
A new pediatric study, its protocol due in nine months
Commitment ExtractorThe supplement approval for Crohn's disease brings a new PREA requirement, a study in patients 6 to 17 years old: the final protocol in nine months, study completion three years after that and the final report six months later. It lands on the biologic's lane as a dashed, proposed date, with the regulatory lead and the clinical owner as owners. On the second product, two promises from the Type B minutes appear the same way: a revised statistical analysis plan for an ongoing study, by a date set in the minutes, and a pediatric formulation bridging plan with the next annual report.
“Proposed · waiting for your signature”
- 04Because of the new approval
Promises outside approval letters
Promise FinderThe new approval makes the Promise Finder re-read the biologic's 63 minutes and responses on file, discussion included. The panel lists the 5 promises it finds: two Health Canada responses already on the timeline, the two new promises on the second product, and one from a Type C meeting that was never tracked.
“Never tracked · filed months ago”
- 05Page 2, Question 3
A shipping validation report that sits in nobody's tracker
Promise FinderIn the Type C minutes for the biologic's prefilled syringe, the sponsor's promise sits in the discussion of Question 3, not in the action items. The minutes were filed with no timeline entry. The lead sees the exact sentence, the page, the date highlighted and the proposed owners: the lead and the CMC owner.
The sponsor agreed to submit a shipping validation report for the 200 mg/mL prefilled syringe to the BLA by a fixed date, months away.
- 06One signature
Added with the meaning of the signature
Regulatory lead“Add to the timeline” opens the promise with its due date fixed by the minutes, the CMC owner as functional owner, and the meaning of the signature: “I approve this timeline entry”. The alerts are already scheduled and the minutes stay linked as the source. The Promise Finder only proposes; nothing reaches the timeline without the lead's signature.
Alerts are scheduled at 90, 60, 30 and 7 days before the due date.
- 07Signed
On the timeline; the CMC owner hears 90 days ahead
Regulatory leadThe promise becomes a solid square on the biologic's lane, Pending, with the Type C minutes as its source. The count of open items goes from 29 to 30. The CMC owner is notified as owner, and the signature is on the activity trail.
“On the timeline · owner notified · alerts set”
- 08The supplement letter
Each item confirmed, edited or rejected, then signed
Regulatory leadThe letter opens beside what the agents found, each with its page and confidence: the new PREA requirement at 97%, the change to the long-term remission registry at 94% with the old and new wording side by side, and a new commitment for a drug-tolerant ADA assay. The distribution reporting reminder is set aside as not a commitment. The lead decides each item and signs; the change to the existing commitment also goes to compliance for countersignature.
“A change to an existing commitment also goes to compliance for countersignature. The original wording stays in the record history.”
- 09The one that will slip
Internal targets missed months before the agency date
Deadline MonitorOn the HMW-limits commitment the Deadline Monitor has raised a slip: three internal targets (25 lots released, 30 lots released, the data review) were missed by 99, 37 and 7 days. The 30th lot is not planned until after the agency date, so that date cannot be met. “Request a new date” drafts the reason in the agency's terms; the new date needs the lead's signature and the compliance countersignature.
“Internal targets from the owner's plan are shown with the agency date. They slip first.”
- 1074 days before it is due
The annual status table, drafted and cited
Status Reporter · regulatory operationsThe biologic's BLA reaches its approval anniversary in two weeks, so its status report under 21 CFR 601.70 is due 60 days after that. The Status Reporter writes one row for each of the 6 requirements and commitments: original and current schedule, the agency status category and an explanation with its evidence. The HMW-limits commitment goes in as Delayed. Regulatory operations reviews; the lead signs.
“Every status uses the agency's words; every explanation cites its evidence.”